Cytarabine Plus Daunorubicin or Idarubicin as Induction Chemotherapy for the Patients with De novo Acute Myelogenous Leukemia.
- Author:
Jin Hee AHN
1
;
Je Hwan LEE
;
Kyoo Hyung LEE
;
Haeseoung BAHNG
;
Jung Hee LEE
;
Jung Shin LEE
;
Sang Hee KIM
;
Woo Kun KIM
Author Information
1. Department of Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
AML;
Cytarabine;
Daunorubicin;
Idarubicin
- MeSH:
Cytarabine*;
Daunorubicin*;
Disease-Free Survival;
Drug Therapy;
Humans;
Idarubicin*;
Induction Chemotherapy*;
Leukemia, Myeloid, Acute*;
Leukemia, Promyelocytic, Acute;
Retrospective Studies
- From:Korean Journal of Hematology
2000;35(3-4):214-221
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: The combination of cytarabine plus anthracycline has been considered standard chemotherapy for acute myelogenous leukemia (AML). We retrospectively analyzed the treatment results of the patients with de novo AML who received cytarabine plus daunorubicin or idarubicin as induction chemotherapy. METHODS: From 1989 to 1998, 149 patients with AML were included. For induction chemotherapy, the patients received cytarabine 100~ 200 mg/m2/day given by continuous 7-day in fusion plus either daunorubicin 40~45 mg/m2/ day (A+D) or idarubicin 12 mg/m2/day (A+I) administered for the first 3 days of treatment. We reviewed clinical records of the patients and analyzed the treatment results such as complete remission (CR) rate, disease free survival (DFS), and overall survival (OS). RESULTS: The CR rates were 67.1% (100 of 149); 69.3% (70 of 101) in A+D group and 62.5 % (30 of 48) in A+I group (P=0.409). The frequent reason of induction failure was resistant disease in A+D group (54.8%) and early death in A+I group (66.7%). The median DFS was 344 days; 344 days in A+D group and 314 days in A+I group. The median OS was 379 days; 389 days in A+D group and 379 days in A+I group. Age < or =60 years and allogeneic BMT as postremission therapy were independent favorable factors both for DFS and OS. AML M3 was favorable factor only for DFS. CONCLUSION: The combination of cytarabine plus daunorubicin or idarubicin was effective for the treatment of AML. We can not find significant difference in CR rate, disease free survival and overall survival between A+D and A+I group.
